Opzelura + ema?

Do you want the current EMA (European Medicines Agency) status for Opzelura, or are you looking for general information about how Opzelura relates to EMA (approval indications, safety, etc.)?

Here’s a quick overview to orient you:

- What Opzelura is: Opzelura is the brand name for ruxolitinib topical cream, a Janus kinase (JAK) inhibitor applied to the skin.

- U.S. context (FDA): In the United States, ruxolitinib topical cream has been approved by the FDA for certain skin conditions (e.g., atopic dermatitis and nonsegmental vitiligo, with specific age indications). The exact approved concentrations and patient ages depend on the indication.

- EMA context (Europe): The European Medicines Agency (EMA) handles marketing authorizations for medicines in the EU. For Opzelura to be sold in the EU, Pfizer (or another sponsor) would submit a marketing authorization application (MAA) to the EMA. The EMA would evaluate efficacy, safety, and quality, then the European Commission would grant the authorization if the CHMP (Committee for Medicinal Products for Human Use) gives a positive opinion.

- Typical status you might see:
- Not yet approved in the EU (application submitted or no submission yet).
- Under review by EMA with a positive/negative CHMP opinion.
- Approved by the European Commission (marketing authorization) for specified EU indications.
- Not approved in the EU with a reason provided (e.g., not meeting efficacy/safety standards or market considerations).

If you’d like, I can look up the latest EMA status for Opzelura and summarize the current EU indications, labeling, and safety notes. Just tell me if you want me to check the current status. Also, if you’re in a specific country (EU member state, UK, etc.), I can tailor the information to that jurisdiction.